Sugi Predict

Sugi Predict / Compounds / SCHEMBL6240318

SCHEMBL6240318

SCHEMBL6240318

COc1ccc2[nH]c(C(=O)O)cc2c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.60
▸ HPGD P15428 3/20 0.60
▸ KMT2A Q03164 6/20 0.55
▸ MEN1 O00255 5/20 0.55
▸ MAPT P10636 4/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ LMNA P02545 3/20 0.55
▸ POLB P06746 1/20 0.55
▸ PTBP1 P26599 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ BLM P54132 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.49
▸ IDO1 P14902 2/20 0.48
▸ TDO2 P48775 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.45
▸ FLT3 P36888 2/20 0.45
▸ SRD5A2 P31213 2/20 0.45
▸ NGFR P08138 1/20 0.44
▸ SRD5A1 P18405 1/20 0.44
▸ PIN1 Q13526 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30403281 1.00 KDM4E (0.60) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL38660125 0.87 KDM4E (0.54) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL4785003 0.86 KMT2A (0.54) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL5564109 0.86 KMT2A (0.57) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL11737870 0.84 KDM4E (0.49) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL1144884 0.84 KDM4E (0.60) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL9314516 0.84 KDM4E (0.60) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL28265787 0.84 KMT2A (0.52) KDM4EHPGDKMT2AMEN1MAPT
SCHEMBL2492396 0.83 IDO1 (0.51) KDM4EHPGDKMT2AMEN1ALDH1A1
SCHEMBL3028151 0.83 KDM4E (0.59) KDM4EHPGDKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 — — CN disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 — — US disclosed
US-20210032202-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD. (SG) 2021-02-04 — — US disclosed
WO-2018073753-A1 FUSED TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS NOVARTIS AG (CH) 2018-04-26 — — WO disclosed
US-9657012-B2 FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-23 — — US disclosed
US-20160355477-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2016-12-08 — — US disclosed
US-9447039-B2 Indole carboxamide derivatives and uses thereof NOVARTIS AG (CH) 2016-09-20 — — US disclosed
EP-2655356-B1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS INC (US) 2016-08-03 — — EP disclosed
CN-103502237-B Faah inhibitor IRONWOOD PHARMACEUTICALS, INC. (US) 2016-01-20 — — CN disclosed
WO-2014037900-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-03-13 — — WO disclosed
CN-103502237-A FAAH inhibitors IRONWOOD PHARMACEUTICALS INC 2014-01-08 — — CN disclosed
EP-2655356-A1 FAAH INHIBITORS Ironwood Pharmaceuticals, Inc. (US) 2013-10-30 — — EP disclosed
WO-2012088469-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-06-28 — — WO disclosed
EP-0828851-B1 TRIPEPTIDYLPEPTIDASE INHIBITORS INST NAT SANTE ETDE LA RECH ME (FR) 2005-07-20 — — EP disclosed
US-6380230-B1 FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS SANOFI-SYNTHELABO (FR) 2002-04-30 — — US disclosed
CN-1276790-A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them SANOFI SA (FR) 2000-12-13 — — CN disclosed
EP-0828851-A2 TRIPEPTIDYLPEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1998-03-18 — — EP disclosed
WO-1996035805-A2 TRIPEPTIDYLPEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1996-11-14 — — WO disclosed
US-4060626-A Indole-carboxylic carbon compounds and pharmaceutical compositions containing them BOEHRINGER MANNHEIM G.M.B.H. (DT) 1977-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 KDM4E 3205/4885HPGD 4005/4885KMT2A 4121/4885
US-20210032202-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF TPH1, TPH2, IARS2 KDM4E 3445/4885HPGD 1015/4885KMT2A 1467/4885
US-20160355477-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF TPH1, TPH2, IARS2 KDM4E 3527/4885HPGD 883/4885KMT2A 1548/4885
US-20220009903-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 KDM4E 3205/4885HPGD 4005/4885KMT2A 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.